Processing your request

please wait...

Case Page


Case Status:    DISMISSED    
On or around 10/07/2020 (Notice of voluntarily dismissal)

Filing Date: September 23, 2020

According to the Complaint, Akcea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases.

This action stems from a proposed transaction announced on August 31, 2020, pursuant to which Akcea Therapeutics, Inc. will be acquired by Ionis Pharmaceuticals, Inc. (“Parent”) and Avalanche Merger Sub, Inc. (“Merger Sub,” and together with Parent, “Ionis”). Parent currently owns approximately 76% of the issued and outstanding shares of Akcea common stock.

On August 30, 2020, Akcea’s Board of Directors caused the Company to enter into an agreement and plan of merger with Ionis. Pursuant to the terms of the Merger Agreement, Merger Sub commenced a tender offer to purchase all of Akcea’s outstanding common stock not already owned by Parent for $18.15 in cash per share. The Tender Offer is set to expire on October 9, 2020.

On September 14, 2020, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

This case was voluntarily dismissed on October 7, 2020.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: AKCA
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Delaware
DOCKET #: 20-CV-01281
JUDGE: Hon. Leonard P. Stark
DATE FILED: 09/23/2020
CLASS PERIOD END: 09/23/2020
  1. Rigrodsky & Long, P.A. (Wilmington)
  2. RM Law, P.C. (Berwyn)
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available